Recent Posts
Featured Posts

Long-Term HannaH Data Support Subcutaneous Trastuzumab for Breast Cancer

Patients with HER2-positive early breast cancerwho received subcutaneous trastuzumab had safety and efficacy outcomes that were noninferior to intravenous trastuzumab, a 6-year follow-up analysis of the open-label, prospective, multicenter, phase III, randomized HannaH trial showed ( identifier: NCT00950300). The long-term trial results were recently published in JAMA Oncology.

Read the full article HERE

Search By Tags
  • Facebook - White Circle
  • Twitter - White Circle
  • Instagram - White Circle
  • LinkedIn - White Circle

Connect with us on social media

© 2021 Care For A Cure, Inc. is a non-profit organization

with a 501(c)(3) tax exempt status. All rights reserved.